ArticleMedicine2016
Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography.Frontiers in pharmacology · 2026Article
- Efficacy and safety of intravitreal injections of conbercept for the treatment of idiopathic choroidal neovascularization.BMC ophthalmology · 2024Article
- Choroidal Vascular Density Quantification in High Myopia with or without Choroidal Neovascularization Using Optical Coherence Tomography Angiography.Journal of ophthalmology · 2023Article
- Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization.Scientific reports · 2021Observational
- IMI Pathologic Myopia.Investigative ophthalmology & visual science · 2021Review
- Presence or absence of choroidal hyper-transmission by SD-OCT imaging distinguishes inflammatory from neovascular lesions in myopic eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Observational
- Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- An overview of the clinical applications of optical coherence tomography angiography.Eye (London, England) · 2018Review
- Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization.Clinical ophthalmology (Auckland, N.Z.) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To observe optical coherence tomography angiography (OCTA) images during follow-up of choroidal neovascularization (CNV) caused by pathological myopia (PM) or idiopathy and discuss OCTA's clinical applicationsPatients with CNV caused by PM or idiopathic CNV (ICNV) were recruited prospectively from the Department of Ophthalmology, West China Hospital from March 2015 to June 2015. Intravitreal injections of Ranibizumab were conducted on all patients and repeated treatments were performed based on examinations of follow-up. Patients received OCTA the first week after injection, together with measurements of best-corrected visual acuity (BCVA) and central macular thickness (CMT). Subsequent follow-up was done once a month.About 10 eyes of 10 patients were included in this study and mean age was (46.20 ± 10.15) years old. Around 6 (60%) were females and the other 4 (40%) were males and 5 were diagnosed with PM and 5 were ICNV. Mean follow-up was (7.82 ± 2.47) weeks. Except 4 (40%) patients got only 1 injection, 5 (50%) received two injections, and 1 (10%) patient got 4 (once every two weeks) due to his treatment-resistant lesion. Endpoint date of this study was on 25th June, 2015. Mean baseline BCVA was (0.81 ± 0.45) logarithm of minimal angle resolution (logMAR) and increased significantly to (0.50 ± 0.40) at last follow-up (P = 0.005). Average CMT of baseline was (276.90 ± 69.73) um and decreased to (249.70 ± 53.37) um at final follow-up with the statistical significance (P = 0.008). OCTA demonstrated details of reduction of CNV size and vessel density simultaneously.OCTA could demonstrate the valid CNV form having advantages of rapid, noninvasive and repeatable. Combination of OCTA and other examinations had a promising future of clinical application on ocular neovascularization diseases. Further studies with larger sample size and longer follow-up are necessary and more advanced OCTA is being expected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.